{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-265755","form_type":"8-K","ticker":"AMGN","cik":"0000318154","company_name":"AMGEN INC","filed_at":"2022-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.143969+00:00","generated_at":"2026-06-23T02:26:00.425074+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amgen completes $3.7B acquisition of ChemoCentryx, adding TAVNEOS to portfolio","bullets":["Acquisition closed at $52 per share in cash, aggregate consideration ~$3.7 billion.","Adds TAVNEOS (avacopan), a first-in-class oral therapy for severe active ANCA-associated vasculitis.","Also includes three early-stage drug candidates targeting chemoattractant receptors and an oral checkpoint for cancer.","TAVNEOS approved by FDA in Oct 2021; being studied in hidradenitis suppurativa and C3 glomerulopathy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-265755","json":"https://secwatch.observer/filing/0001193125-22-265755.json","markdown":"https://secwatch.observer/filing/0001193125-22-265755.md","text":"https://secwatch.observer/filing/0001193125-22-265755.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318154/000119312522265755/0001193125-22-265755-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318154/000119312522265755/d414605d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T02:26:00.425074+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}